News Sentiment

ARWR sentiment intelligence

Arrowhead Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 81.82 Week of 19 Jun 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+9.8% over one week, +9.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 9.8% Price confirming higher
Trend fit Trend active 9.2% over four weeks
Fair value 148.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
simplywall.st 11
Market source 8
Business Wire 5
Sahm 2
TradingKey 2
Quiver Quantitative 2
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 16
Regulatory and legal 1
Balance sheet 1
Analyst action 1
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Insider Monkey Direct company coverage

Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026

Bernstein has increased its price target for Arrowhead Pharmaceuticals (ARWR) to $46 from $35, while maintaining a Market Perform rating. This adjustment follows a strong start to 2026 for the biotech sector, with ARWR outperforming the market. The company also reported positive

Tone
Neutral 50/100
Event
Analyst action
Published
27 May 2026 06:10
Source
Insider Monkey
Simply Wall Street Direct company coverage

ARWR - Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships

Analysts have increased their price targets for Arrowhead Pharmaceuticals ($ARWR) due to the FDA approval of Redemplo, a stronger commercial outlook for familial chylomicronemia syndrome and severe hypertriglyceridemia (sHTG), and long-term cost and margin advantages. While bulli

Tone
Positive 74/100
Event
Earnings
Published
26 May 2026 18:09
Source
Simply Wall Street